Exchange: OTC·Updated 03:56 PM EST

BVAXF Biovaxys Technology Corp

$0.09
$0.001
(1.12%)
Today
Mkt Cap$3.92M
Vol18,764.00

About BVAXF

BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.
64

Bullish Sentiment

How do you feel about BVAXF?

NewMexicats
$BVAXF $BIOV.CSE NEW TWEET The DoD is establishing a network of prequalified biotechnology partners that can participate in future medical countermeasure development projects. The government's official JETT description specifically says the objective is to streamline follow-on project awards and establish longer-term relationships with participating companies. In other words, BioVaxys is seeking potential access to a contracting framework, not merely responding to one possible vaccine project. I found something else interesting: the PBA announcement was substantially updated on November 17, just two days before this tweet. Its scope now explicitly includes biologics, medical devices, diagnostics and broader medical countermeasures.
3
FLArnot
$BVAXF 6 months of halt (for failure to comply with regulations) in a few days. They are in full blown delisting territory at this point.
2
StockEnthusiast1
$BVAXF my question is (especially for a company with very very little revenue) how messed up can financials possibly be to default this long on filings??? In the investment world this is a MASSIVE RED FLAG that something very negative is going on behind the scenes.
1
Ventureville
$BVAXF Moderna/Merck just showed their personalized cancer vaccine + Keytruda still holding durable benefit at 5 years in melanoma.
Ventureville
$BVAXF Same time, a bunch of groups are working on better mRNA/antigen delivery (less reactogenic LNPs, depots, targeted systems).
Ventureville
$BVAXF That backdrop makes DPX’s lipid depot approach for sustained T-cell responses look more relevant, especially with the PESCO combo data already out.
Davidendz
$BVAXF Clinical side still shows activity with MVP-S + Keytruda + cyclo in ovarian and bladder, and the platform keeps getting government looks.
ProfitWhisperer
$BVAXF $BIOV.CSE Quick context on PESCO. The 40% ORR is for platinum-sensitive ovarian patients. Overall the ORR was 24%, with an 82% disease control rate. The company reported those numbers in January, and the trial was published in Nature Communications in May. It’s small and open-label, so I’d call it a signal. Filings are still the gate for the stock.
ProfitWhisperer
$BVAXF $BIOV.CSE Watching for BioVaxys’ response to the RFI from JETT CBRN. The company says the next step is on its side. A submission would be the first real signal.
ProfitWhisperer
$BVAXF $BIOV.CSE BioVaxys’ fiscal year ended October 31. Based on the deadline for the last annual filing (Feb 28), the next annual filing would fall due around late February. The Merck KGaA term sheet on survivin access is the latest partnering step the company has announced. Filings are the next checkpoint.
Davidendz
$BVAXF Company posted Oct 6 they’re structuring multiple collabs (MVP-S + anti-PD-1s, new DPX peptide formulations) plus a joint proposal into the $80M+ Singleshield Prize for a single-dose H5N1 platform.
Davidendz
$BVAXF They said early Oct they’re structuring MVP-S + anti-PD-1 collabs and submitted into an $80M single-dose H5N1 prize.
wheresdannynow
$BVAXF Still more focused on the survivin access and combo discussions than the website timing.
wheresdannynow
$BVAXF Once the fixes are applied and the content update goes live, it’ll be clearer whether it adds anything on the pipeline or partnering side.
wheresdannynow
$BVAXF The more relevant signal remains the live Merck term sheet on MVP-S + checkpoint combinations.

Advertisement|Remove ads.